amphetamine has been researched along with Body Weight in 187 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 7.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| " Furthermore, the presence or absence of maternal weight loss predicted MK-801 and amphetamine stimulated locomotor abnormalities in offspring." | 3.77 | Individual differences in maternal response to immune challenge predict offspring behavior: contribution of environmental factors. ( Ahlbrand, R; Bronson, SL; Horn, PS; Kern, JR; Richtand, NM, 2011) |
| " Post-weaning exposure to SD increased body weight, body fat, and plasma leptin levels, as well as the plasma glucose response to glucose challenge, compared to chow-fed rats." | 3.76 | Long-term physiological and behavioral effects of exposure to a highly palatable diet during the perinatal and post-weaning periods. ( Frate, C; Schuster, K; Shalev, U; Tobin, S; Tylor, A; Woodside, B, 2010) |
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 3.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| " Compared to control animals, MD rats showed (1) a reduction in body weight, (2) an increased in reversal latency in negative geotaxis, (3) a delayed eye opening, (4) a delayed emergence of walking and rearing; and (5) a delayed emergence of the behavioural response to amphetamine (amph)." | 3.73 | Early maternal deprivation retards neurodevelopment in Wistar rats. ( Derks, N; Ellenbroek, BA; Park, HJ, 2005) |
| "The symptom of "diminished interest or pleasure" in rewarding stimuli is an affective symptom of nicotine and amphetamine withdrawal, and a core symptom of depression." | 3.71 | Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. ( Harrison, AA; Liem, YT; Markou, A, 2001) |
| "Because AZT (azidothymidine, zidovudine, ZDV) has become the standard of care for preventing HIV transmission during pregnancy, we conducted a study to assess the possible neurobehavioral effects of this drug, using a rat model." | 3.70 | Neurobehavioral effects of perinatal AZT exposure in Sprague-Dawley weaning rats. ( Busidan, Y; Dow-Edwards, DL, 1999) |
| "Three drugs that affect the neuroendocrine system (amphetamine, methylphenidate, and codeine) caused decreases in body weights and in the incidence of spontaneously occurring mammary gland neoplasms in the female F344/N rat in 2-year carcinogenicity studies." | 3.69 | Decreased incidence of spontaneous mammary gland neoplasms in female F344 rats treated with amphetamine, methylphenidate, or codeine. ( Dunnick, JK; Elwell, MR; Haseman, JK, 1996) |
| " Yet, analysis of the body weight gain and volumetric determinations of brain areas have not been performed by comparing the effects of neonatal exposure to cocaine and amphetamine." | 3.68 | Body weight gain and hippocampal volumes of rats exposed neonatally to psychostimulants. ( Silva, MC; Tavares, MA, 1993) |
| "The effects of intake of an amphetamine solution on food and fluid intakes, body weight (b." | 3.68 | Dietary modulation of the anorectic potency of amphetamine. ( Kanarek, RB; Marks-Kaufman, R, 1990) |
| " The lateralized decrease in elicited feeding was correlated with postlesion body weight loss, striatal catecholamine depletion (dopamine, 94%; norepinephrine, 52%) and amphetamine-induced ipsilateral turning, and can be characterized as an inability of the lesioned nigrostriatal system to maintain the CSD-elicited response rather than a failure to induce it." | 3.66 | Lateralized hunger: ipsilateral attenuation of cortical spreading depression-induced feeding after unilateral 6-OHDA injection into the substantia nigra. ( Hefti, F; Huston, JP; Lichtensteiger, W; Siegfried, B, 1979) |
| " In some patients, weight regain may be prevented by giving the drug long term but the complications of long-term administration have yet to be evaluated." | 2.37 | The current status of antiobesity drugs. ( Farquhar, DL; Galloway, SM; Munro, JF, 1984) |
| "Besides seizures, patients with epilepsy are affected by a variety of cognitive and psychiatric comorbidities that further impair their quality of life." | 1.48 | 6 Hz corneal kindling in mice triggers neurobehavioral comorbidities accompanied by relevant changes in c-Fos immunoreactivity throughout the brain. ( Albertini, G; De Bundel, D; Demuyser, T; Massie, A; Smolders, I; Walrave, L, 2018) |
| "Amphetamine (AMPH) treatment can suppress appetite and increase oxidative stress in the brain." | 1.42 | Involvement of oxidative stress in the regulation of NPY/CART-mediated appetite control in amphetamine-treated rats. ( Chen, CH; Chen, PN; Hsieh, YS; Kuo, DY; Tsai, TT; Yu, CH, 2015) |
| " Dose-response assessments demonstrated that rats housed in EE showed reduced sensitivity to the behavioural effects of DZP and DMI but increased sensitivity to the locomotor-enhancing effects of AMP compared to SC and IC; while IC animals exhibited the clearest dose-response effects to increasing doses of DMI." | 1.38 | The effects of isolated and enriched housing conditions on baseline and drug-induced behavioural responses in the male rat. ( Kelly, JP; Simpson, J, 2012) |
| "5 mg/kg) were examined in the parietal cortex of rats pretreated for nine days with either saline, non-neurotoxic amphetamine, or neurotoxic AMPH dosing regimens." | 1.34 | A threshold neurotoxic amphetamine exposure inhibits parietal cortex expression of synaptic plasticity-related genes. ( Bowyer, JF; Delongchamp, RR; Freeman, WM; O'Callaghan, JP; Patel, KM; Pogge, AR; Vrana, KE, 2007) |
| " The present experiments were performed in order to obtain more information on the relationship between the OX-induced sensitization to AMPH and the OX dose and dosing regime (single or repeated), and to find out whether the environment associated with the acute effects of OX could affect the response to AMPH." | 1.32 | Alteration in behavioral sensitivity to amphetamine after treatment with oxotremorine. Effect of dose and test environment. ( Gralewicz, S; Lutz, P; Tomas, T; Wiaderna, D, 2003) |
| "Amphetamine-pretreated animals demonstrated a transient increase in errors on nonsignal trials following escalating amphetamine administration." | 1.32 | Transient disruption of attentional performance following escalating amphetamine administration in rats. ( Burk, JA; Kondrad, RL, 2004) |
| "Weight gain is one side effect of many antipsychotic drugs (APDs)." | 1.31 | Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. ( Bubser, M; Deutch, AY; Fadel, J, 2002) |
| " Our previous studies show that chronic administration of NPE does not produce the typical amphetamine hyperdipsic response." | 1.29 | Tolerance does not develop to the suppressant effects of (-)-norpseudoephedrine on ingestive behavior in the rat. ( Fraioli, S; Nencini, P; Perrella, D, 1996) |
| " Survival was similar in dosed and control groups." | 1.28 | Decreases in spontaneous tumors in rats and mice after treatment with amphetamine. ( Dunnick, JK; Eustis, SL, 1991) |
| "Quinpirole sensitivity was reduced in amphetamine-treated rats only following acute SKF 38393 pretreatment." | 1.28 | Repeated amphetamine: reduced dopamine neuronal responsiveness to apomorphine but not quinpirole. ( Chiodo, LA; Freeman, AS; Kelland, MD; Pitts, DK, 1989) |
| "This study compared the effects of chronic administration of anorexigenic drugs on weight loss in mice." | 1.27 | An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice. ( Flood, JF; Morley, JE, 1987) |
| "Also, a magnesium deficiency is capable of altering the potency of catecholamine stimulating drugs." | 1.27 | Magnesium deficiency alters aggressive behavior and catecholamine function. ( Kantak, KM, 1988) |
| "Amphetamine-treated rats developed tolerance to these ingestive effects and to weight loss, whereas nicotine-injected rats did not." | 1.26 | Nicotine and amphetamine: differential tolerance and no cross-tolerance for ingestive effects. ( Baettig, K; Classen, W; Martin, JR, 1980) |
| "Amphetamine was included for comparison purposes." | 1.26 | Anorexigenic effects of two amines obtained from Catha edulis Forsk. (Khat) in rats. ( Carlini, EA; Zelger, JL, 1980) |
| "Since any drug treatment of obesity interferes with the patient's motivation to subject himself to the prolonged and possibly life-long changes in his eating habits and exertional behavior which are mandatory for the achievement of long-term therapeutic success, the use of drugs is rarely indicated in the treatment of obesity and should remain the exception." | 1.25 | [Mode of action and indication for appetite depressants in the treatment of obesity]. ( Stauffacher, W, 1975) |
| "6 Animals withdrawn following chronic administration of a number of drugs, barbitone, barbitone/bemegride mixture, Mandrax (methaqualone: diphenhydramine; 10: 1), chlordiazepoxide, nitrazepam, chlorpromazine or ethanol, exhibited a significant tolerance to intracerebroventricularly administered pentobarbitone." | 1.25 | A study of the factors affecting the sleeping time following intracerebroventricular administration of pentobarbitone sodium: effect of prior administration of centrally active drugs. ( Stevenson, IH; Turnbull, MJ, 1974) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 101 (54.01) | 18.7374 |
| 1990's | 28 (14.97) | 18.2507 |
| 2000's | 33 (17.65) | 29.6817 |
| 2010's | 24 (12.83) | 24.3611 |
| 2020's | 1 (0.53) | 2.80 |
| Authors | Studies |
|---|---|
| Potrebić, MS | 1 |
| Pavković, ŽZ | 1 |
| Srbovan, MM | 1 |
| Dmura, GM | 1 |
| Pešić, VT | 1 |
| Pasquarelli, N | 1 |
| Voehringer, P | 1 |
| Henke, J | 1 |
| Ferger, B | 1 |
| Albertini, G | 1 |
| Walrave, L | 1 |
| Demuyser, T | 1 |
| Massie, A | 1 |
| De Bundel, D | 1 |
| Smolders, I | 1 |
| Thwaites, SJ | 1 |
| van den Buuse, M | 3 |
| Gogos, A | 2 |
| Smith, MA | 1 |
| Pennock, MM | 1 |
| Pitts, EG | 1 |
| Walker, KL | 1 |
| Lang, KC | 1 |
| Johnston, CE | 1 |
| Herschel, DJ | 1 |
| Lasek, AW | 1 |
| Hammer, RP | 1 |
| Nikulina, EM | 1 |
| Walker, PD | 1 |
| Jarosz, PA | 1 |
| Bouhamdan, M | 1 |
| MacKenzie, RG | 1 |
| Peng, XX | 1 |
| Lister, A | 1 |
| Rabinowitsch, A | 1 |
| Kolaric, R | 1 |
| Cabeza de Vaca, S | 1 |
| Ziff, EB | 1 |
| Carr, KD | 1 |
| Hsieh, YS | 3 |
| Chen, PN | 2 |
| Yu, CH | 2 |
| Chen, CH | 1 |
| Tsai, TT | 1 |
| Kuo, DY | 5 |
| Fukushiro, DF | 1 |
| Olivera, A | 1 |
| Liu, Y | 1 |
| Wang, Z | 1 |
| Linden, J | 1 |
| Van de Beeck, L | 1 |
| Plumier, JC | 1 |
| Ferrara, A | 1 |
| Mazitov, T | 1 |
| Bregin, A | 1 |
| Philips, MA | 1 |
| Innos, J | 1 |
| Vasar, E | 1 |
| Chu, SC | 1 |
| Faraone, SV | 2 |
| Biederman, J | 2 |
| Morley, CP | 1 |
| Spencer, TJ | 1 |
| Sevak, RJ | 4 |
| Koek, W | 3 |
| Owens, WA | 4 |
| Galli, A | 5 |
| Daws, LC | 4 |
| France, CP | 4 |
| Romeas, T | 1 |
| Morissette, MC | 1 |
| Mnie-Filali, O | 1 |
| Piñeyro, G | 1 |
| Boye, SM | 1 |
| HARRIS, SC | 1 |
| IVY, AC | 1 |
| SEARLE, LM | 1 |
| Doremus-Fitzwater, TL | 2 |
| Spear, LP | 2 |
| Der-Avakian, A | 1 |
| Markou, A | 2 |
| Shalev, U | 1 |
| Tylor, A | 1 |
| Schuster, K | 1 |
| Frate, C | 1 |
| Tobin, S | 1 |
| Woodside, B | 1 |
| Vorhees, CV | 1 |
| He, E | 1 |
| Skelton, MR | 1 |
| Graham, DL | 1 |
| Schaefer, TL | 1 |
| Grace, CE | 1 |
| Braun, AA | 1 |
| Amos-Kroohs, R | 1 |
| Williams, MT | 1 |
| Chavez, C | 1 |
| Hill, R | 1 |
| Van Sinderen, M | 1 |
| Simpson, E | 1 |
| Boon, WC | 1 |
| Bronson, SL | 1 |
| Ahlbrand, R | 1 |
| Horn, PS | 1 |
| Kern, JR | 1 |
| Richtand, NM | 1 |
| Slamberová, R | 1 |
| Schutová, B | 1 |
| Hrubá, L | 1 |
| Pometlová, M | 1 |
| Williams, JM | 1 |
| Saunders, C | 1 |
| Avison, MJ | 1 |
| Bocarsly, ME | 1 |
| Barson, JR | 1 |
| Hauca, JM | 1 |
| Hoebel, BG | 2 |
| Leibowitz, SF | 2 |
| Avena, NM | 1 |
| Simpson, J | 1 |
| Kelly, JP | 1 |
| Hawken, ER | 1 |
| Lister, J | 1 |
| Winterborn, AN | 1 |
| Beninger, RJ | 1 |
| Fadel, J | 1 |
| Bubser, M | 1 |
| Deutch, AY | 1 |
| Bizarro, L | 1 |
| Stolerman, IP | 1 |
| SHAPIRO, SL | 1 |
| FREEDMAN, L | 1 |
| FELDMAN, HS | 1 |
| MUKERJEE, SS | 1 |
| SARKAR, AK | 1 |
| MUKHERJEE, SK | 1 |
| CHRISTIAN, JE | 1 |
| COMBS, LW | 1 |
| KESSLER, WV | 1 |
| JOHANNESSEN, SG | 1 |
| FLEURY, C | 1 |
| FAMILY, S | 1 |
| FROMMEL, E | 1 |
| OSTER, HL | 1 |
| MEDLAR, RE | 1 |
| Gralewicz, S | 1 |
| Lutz, P | 1 |
| Wiaderna, D | 1 |
| Tomas, T | 1 |
| Ayalon, L | 1 |
| Doron, R | 1 |
| Weiner, I | 1 |
| Joel, D | 1 |
| Yasuhara, T | 2 |
| Shingo, T | 2 |
| Kobayashi, K | 1 |
| Takeuchi, A | 1 |
| Yano, A | 1 |
| Muraoka, K | 2 |
| Matsui, T | 1 |
| Miyoshi, Y | 1 |
| Hamada, H | 2 |
| Date, I | 2 |
| Kondrad, RL | 1 |
| Burk, JA | 1 |
| Levant, B | 1 |
| Radel, JD | 1 |
| Carlson, SE | 1 |
| Mamczarz, J | 1 |
| Bowker, JL | 1 |
| Duffy, K | 1 |
| Zhu, M | 1 |
| Hagepanos, A | 1 |
| Ingram, DK | 1 |
| Steensland, P | 1 |
| Hallberg, M | 1 |
| Kindlundh, A | 1 |
| Fahlke, C | 1 |
| Nyberg, F | 1 |
| Monuteaux, M | 1 |
| Spencer, T | 1 |
| Kinkead, B | 1 |
| Dobner, PR | 1 |
| Egnatashvili, V | 1 |
| Murray, T | 1 |
| Deitemeyer, N | 1 |
| Nemeroff, CB | 1 |
| Galici, R | 1 |
| Chang, X | 1 |
| Javors, MA | 1 |
| Kameda, M | 1 |
| Agari, T | 1 |
| Wen Ji, Y | 1 |
| Hayase, H | 1 |
| Borlongan, CV | 1 |
| Ellenbroek, BA | 1 |
| Derks, N | 1 |
| Park, HJ | 1 |
| Moffett, M | 1 |
| Stanek, L | 1 |
| Harley, J | 1 |
| Rogge, G | 1 |
| Asnicar, M | 1 |
| Hsiung, H | 1 |
| Kuhar, M | 1 |
| Bowyer, JF | 1 |
| Pogge, AR | 1 |
| Delongchamp, RR | 1 |
| O'Callaghan, JP | 1 |
| Patel, KM | 1 |
| Vrana, KE | 1 |
| Freeman, WM | 1 |
| Garner, B | 1 |
| Wood, SJ | 1 |
| Pantelis, C | 1 |
| Angelucci, F | 1 |
| Gruber, SH | 1 |
| El Khoury, A | 1 |
| Tonali, PA | 1 |
| Mathé, AA | 1 |
| Yang, SF | 1 |
| Chiou, HL | 1 |
| Wallace-Boone, TL | 1 |
| Newton, AE | 1 |
| Wright, RN | 1 |
| Lodge, NJ | 1 |
| McElroy, JF | 1 |
| Kuan, WL | 1 |
| Zhao, JW | 1 |
| Barker, RA | 1 |
| McDougall, SA | 2 |
| Reichel, CM | 1 |
| Farley, CM | 1 |
| Flesher, MM | 1 |
| Der-Ghazarian, T | 1 |
| Cortez, AM | 1 |
| Wacan, JJ | 1 |
| Martinez, CE | 1 |
| Varela, FA | 1 |
| Butt, AE | 1 |
| Crawford, CA | 2 |
| Vacher, J | 1 |
| Lakatos, C | 1 |
| Rispat, G | 1 |
| Duchêne-Marullaz, P | 1 |
| Meginniss, RF | 1 |
| Blundell, JE | 4 |
| Tombros, E | 1 |
| Rogers, PJ | 1 |
| Latham, CJ | 1 |
| Galloway, SM | 1 |
| Farquhar, DL | 1 |
| Munro, JF | 1 |
| Wyllie, MG | 1 |
| Fletcher, A | 1 |
| Rothwell, NJ | 1 |
| Stock, MJ | 1 |
| McDermott, LJ | 1 |
| Grossman, SP | 3 |
| Hammer, NJ | 1 |
| Brown, LL | 1 |
| Bermann, MC | 1 |
| Berthelot, P | 1 |
| Bonte, JP | 1 |
| Debaert, M | 1 |
| Lesieur, D | 1 |
| Brunet, C | 1 |
| Cazin, M | 1 |
| Lesieur, I | 1 |
| Luyckx, M | 1 |
| Cazin, JC | 1 |
| Levitsky, DA | 2 |
| Strupp, BJ | 2 |
| Lupoli, J | 1 |
| Leshem, M | 1 |
| Baettig, K | 1 |
| Martin, JR | 1 |
| Classen, W | 1 |
| Zelger, JL | 1 |
| Carlini, EA | 1 |
| Willner, P | 2 |
| Montgomery, T | 1 |
| Allen, LF | 2 |
| Winn, P | 2 |
| Sakai, K | 1 |
| Gash, DM | 1 |
| Draski, LJ | 1 |
| Nash, DJ | 1 |
| Gerhardt, GA | 1 |
| Martin-Iverson, MT | 1 |
| Todd, KG | 1 |
| Altar, CA | 1 |
| Sauer, H | 1 |
| Fischer, W | 1 |
| Nikkhah, G | 1 |
| Wiegand, SJ | 2 |
| Brundin, P | 1 |
| Lindsay, RM | 1 |
| Björklund, A | 2 |
| Tavares, MA | 3 |
| Silva, MC | 3 |
| Yurek, DM | 1 |
| Lu, W | 1 |
| Hipkens, S | 1 |
| Dunnick, JK | 2 |
| Elwell, MR | 1 |
| Haseman, JK | 1 |
| Dell'Omo, G | 1 |
| Fiore, M | 1 |
| Petruzzi, S | 1 |
| Alleva, E | 1 |
| Bignami, G | 1 |
| Nencini, P | 1 |
| Fraioli, S | 1 |
| Perrella, D | 1 |
| Matthews, K | 1 |
| Hall, FS | 1 |
| Wilkinson, LS | 1 |
| Robbins, TW | 1 |
| Inglis, WL | 1 |
| Silva-Araújo, A | 1 |
| Xavier, MR | 1 |
| Ali, SF | 2 |
| Choi-Lundberg, DL | 1 |
| Lin, Q | 1 |
| Schallert, T | 1 |
| Crippens, D | 1 |
| Davidson, BL | 1 |
| Chang, YN | 1 |
| Chiang, YL | 1 |
| Qian, J | 1 |
| Bardwaj, L | 1 |
| Bohn, MC | 1 |
| Rosenblad, C | 1 |
| Kirik, D | 1 |
| Devaux, B | 1 |
| Moffat, B | 1 |
| Phillips, HS | 1 |
| Busidan, Y | 1 |
| Dow-Edwards, DL | 1 |
| Zavala, AR | 1 |
| Karper, PE | 1 |
| Abbott, DL | 1 |
| Figueroa, S | 1 |
| Harrison, AA | 1 |
| Liem, YT | 1 |
| Sohn, EH | 1 |
| Wolden-Hanson, T | 1 |
| Matsumoto, AM | 1 |
| Sund, AM | 1 |
| Zeiner, P | 1 |
| Hsu, CT | 1 |
| Cheng, JT | 1 |
| Gralla, EJ | 1 |
| Sabo, JP | 1 |
| Hayden, DW | 1 |
| Yochmowitz, MG | 1 |
| Mattsson, JL | 1 |
| Leshem, MB | 3 |
| Morrison, P | 1 |
| Rosenmann, M | 1 |
| Thornhill, JA | 1 |
| Hirst, M | 1 |
| Gowdey, CW | 1 |
| Siegfried, B | 1 |
| Hefti, F | 1 |
| Lichtensteiger, W | 1 |
| Huston, JP | 1 |
| Airaksinen, MM | 1 |
| Ho, BT | 1 |
| An, R | 1 |
| Taylor, D | 1 |
| Kostas, J | 1 |
| McFarland, DJ | 1 |
| Drew, WG | 1 |
| Arnold, LE | 2 |
| Huestis, RD | 1 |
| Smeltzer, DJ | 1 |
| Scheib, J | 1 |
| Wemmer, D | 1 |
| Colner, G | 1 |
| Lefkowitz, SS | 1 |
| Nemeth, D | 1 |
| McHugh, PR | 1 |
| Gibbs, J | 1 |
| Falasco, JD | 1 |
| Moran, T | 1 |
| Smith, GP | 1 |
| Isaacson, RL | 1 |
| Fish, BS | 1 |
| Lanier, LP | 1 |
| Dunn, AJ | 1 |
| Crow, TJ | 1 |
| Longden, A | 1 |
| Smith, A | 1 |
| Wendlandt, S | 1 |
| Ghosh, MN | 1 |
| Parvathy, S | 1 |
| Kobayashi, M | 1 |
| Arai, E | 1 |
| Stauffacher, W | 1 |
| Mabry, PD | 1 |
| Campbell, BA | 3 |
| Götestam, KG | 1 |
| Lewander, T | 2 |
| Kelly, PH | 1 |
| Seviour, PW | 1 |
| Iversen, SD | 1 |
| Lytle, LD | 2 |
| Banerjee, U | 1 |
| Blanchard, BA | 1 |
| LeFevre, R | 1 |
| Mankes, RF | 1 |
| Glick, SD | 1 |
| Terlouw, EM | 1 |
| Lawrence, AB | 1 |
| Illius, AW | 1 |
| Zimmerberg, B | 2 |
| Brett, MB | 1 |
| Shartrand, AM | 1 |
| Swerdlow, NR | 1 |
| Hauger, R | 1 |
| Irwin, M | 1 |
| Koob, GF | 1 |
| Britton, KT | 1 |
| Pulvirenti, L | 1 |
| Peris, J | 1 |
| Decambre, N | 1 |
| Coleman-Hardee, ML | 1 |
| Simpkins, JW | 1 |
| Phillips, G | 1 |
| Sampson, D | 1 |
| Nunn, J | 1 |
| Muscat, R | 1 |
| Lall, SB | 1 |
| Sahoo, RN | 1 |
| Eustis, SL | 1 |
| Nickel, B | 1 |
| Schulze, G | 1 |
| Szelenyi, I | 1 |
| Marks-Kaufman, R | 1 |
| Kanarek, RB | 1 |
| Scalzo, FM | 1 |
| Holson, RR | 1 |
| Gough, BJ | 1 |
| Pitts, DK | 1 |
| Freeman, AS | 1 |
| Kelland, MD | 1 |
| Chiodo, LA | 1 |
| Cass, WA | 1 |
| Bowman, JP | 1 |
| Elmund, JK | 1 |
| Fride, E | 1 |
| Weinstock, M | 1 |
| Rosen, JB | 1 |
| Young, AM | 1 |
| Beuthin, FC | 1 |
| Louis-Ferdinand, RT | 1 |
| Morley, JE | 1 |
| Flood, JF | 1 |
| Levy, AD | 1 |
| Ellison, GD | 1 |
| Kantak, KM | 1 |
| Hunsinger, RN | 1 |
| Kibbe, AH | 1 |
| Wilson, MC | 1 |
| Eichlseder, W | 1 |
| Stevenson, IH | 1 |
| Turnbull, MJ | 1 |
| Babington, RG | 1 |
| Wedeking, PW | 1 |
| Platt, DS | 1 |
| Cockrill, BL | 1 |
| Guzek, JW | 1 |
| Leśnik, H | 1 |
| Leonard, BE | 1 |
| Lynn, EJ | 1 |
| Ahlskog, JE | 1 |
| Barrett, AM | 1 |
| Gluckman, MI | 1 |
| Baum, T | 1 |
| Niemegeers, CJ | 1 |
| Janssen, PA | 1 |
| Alhava, E | 1 |
| Mattila, MJ | 1 |
| Rosen, AJ | 1 |
| Freedman, PE | 1 |
| Parkes, JD | 1 |
| Fenton, G | 1 |
| Struthers, G | 1 |
| Curzon, G | 1 |
| Kantamaneni, BD | 1 |
| Buxton, BH | 1 |
| Record, C | 1 |
| Bentwich, T | 1 |
| Bentwich, Z | 1 |
| Wender, PH | 1 |
| McCloskey, K | 1 |
| Snyder, SH | 1 |
| Court, JM | 1 |
| Cooper, BR | 1 |
| Breese, GR | 1 |
| Asher, WL | 1 |
| Dietz, RE | 1 |
| Gemignani, A | 1 |
| Versace, P | 1 |
| Cugurra, F | 1 |
| Vaccari, A | 1 |
| Coleoni, AH | 1 |
| Neill, DB | 2 |
| Grant, LD | 1 |
| Russek, M | 2 |
| Rodríguez-Zendejas, AM | 1 |
| Teitelbaum, P | 1 |
| Taylor, M | 1 |
| Goudie, AJ | 1 |
| Williams, A | 1 |
| Green, RS | 1 |
| Rau, JH | 1 |
| Fuller, RW | 1 |
| Snoddy, HD | 1 |
| Bernier, A | 1 |
| Sicot, N | 1 |
| Le Douarec, JC | 1 |
| Sirtori, C | 1 |
| Hurwitz, A | 1 |
| Azarnoff, DL | 1 |
| Ho, AK | 1 |
| Gershon, S | 1 |
| Overstreet, DH | 1 |
| Hadick, DG | 1 |
| Russell, RW | 1 |
| Vree, TB | 1 |
| Muskens, AT | 1 |
| van Rossum, JM | 1 |
| Herman, ZS | 1 |
| Trzeciak, H | 1 |
| Chruściel, TL | 1 |
| Kmieciak-Kolada, K | 1 |
| Drybański, A | 1 |
| Sokola, A | 1 |
| Opitz, K | 1 |
| Weischer, ML | 1 |
| Klose, L | 1 |
| Moorcroft, WH | 1 |
| Yelnosky, J | 2 |
| Panasevich, RE | 1 |
| Borrelli, AR | 1 |
| Lawlor, RB | 2 |
| Trivedi, MC | 1 |
| Wade, GN | 1 |
| Zucker, I | 1 |
| Mann, GV | 1 |
| Borowitz, JL | 1 |
| Kennedy, JR | 1 |
| Blum, JE | 1 |
| Reynolds, RW | 1 |
| Yasuda, M | 1 |
| Ariyuki, F | 1 |
| Nishimura, H | 1 |
| Borbély, A | 1 |
| Waser, PG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1(Mecasermin [rDNA] Injection)[NCT01777542] | Phase 2 | 30 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The ABC-C is a global behavior checklist implemented for the measurement of drug and other treatment effects in populations with intellectual disability. Behavior based on 58 items that describe various behavioral problems.~Each item is rated on the parents perceived severity of the behavior. The answer options for each item are:~0 = Not a problem~= Problem but slight in degree~= Moderately serious problem~= Severe in degree~The measure is broken down into the following subscales with individual ranges as follows:~Subscale I (Irritability): 15 items, score range = 0-45 Subscale II (Lethargy): 16 items, score range = 0-48 Subscale III (Stereotypy): 7 items, score range = 0-21 Subscale IV (Hyperactivity): 16 items, score range = 0-48 Subscale V (Inappropriate Speech) was not included in the breakdown because it was not applicable (no participants in the study had verbal language)." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Subscale I | Visit 3 - First Intervention: Subscale I | Visit 5 - First Intervention: Subscale I | Visit 6 - Second Intervention: Subscale I | Visit 8 - Second Intervention: Subscale I | Visit 10 - Second Intervention: Subscale I | Follow-up: Subscale I (Irritability) | Visit 1 - First Intervention: Subscale II | Visit 3 - First Intervention: Subscale II | Visit 5 - First Intervention: Subscale II | Visit 6 - Second Intervention: Subscale II | Visit 8 - Second Intervention: Subscale II | Visit 10 - Second Intervention: Subscale II | Follow-up: Subscale II (Lethargy) | Visit 1 - First Intervention: Subscale III | Visit 3 - First Intervention: Subscale III | Visit 5 - First Intervention: Subscale III | Visit 6 - Second Intervention: Subscale III | Visit 8 - Second Intervention: Subscale III | Visit 10 - Second Intervention: Subscale III | Follow-up: Subscale III (Stereotypy) | Visit 1 - First Intervention: Subscale IV | Visit 3 - First Intervention: Subscale IV | Visit 5 - First Intervention: Subscale IV | Visit 6 - Second Intervention: Subscale IV | Visit 8 - Second Intervention: Subscale IV | Visit 10 - Second Intervention: Subscale IV | Follow-up: Subscale IV (Hyperactivity) | |
| Placebo First, Then rhIGF-1 | 9.00 | 9.00 | 7.00 | 7.00 | 4.00 | 5.00 | 3.00 | 13.00 | 11.00 | 9.00 | 11.00 | 8.00 | 6.00 | 6.00 | 13.00 | 10.00 | 11.00 | 11.00 | 10.00 | 8.00 | 8.00 | 13.00 | 12.00 | 11.00 | 11.00 | 7.00 | 10.00 | 9.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 2.00 | 4.00 | 3.00 | 5.00 | 2.00 | 8.00 | 7.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.00 | 12.00 | 10.00 | 9.00 | 11.00 | 9.00 | 9.00 | 9.00 | 8.00 | 8.00 | 6.00 | 7.00 | 4.00 | 5.00 | 5.00 |
"Remaining subscales of the ADAMS that are not primary outcome measures include: Manic/hyperactive, Depressed mood, General anxiety, Obsessive/compulsive behavior.~The range for each subscale is as follows:~Manic/Hyperactive Behavior: 0-15 Depressed Mood: 0-21 General Anxiety: 0-21 Obsessive/Compulsive Behavior: 0-9~The higher the score for each subscale, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Manic/Hyperactive | Visit 2- First Intervention: Manic/Hyperactive | Visit 3- First Intervention: Manic/Hyperactive | Visit 4- First Intervention: Manic/Hyperactive | Visit 5- First Intervention: Manic/Hyperactive | Visit 6- Second Intervention: Manic/Hyperactive | Visit 7- Second Intervention: Manic/Hyperactive | Visit 8- Second Intervention: Manic/Hyperactive | Visit 9- Second Intervention: Manic/Hyperactive | Visit 10- First Intervention: Manic/Hyperactive | Follow-up: Manic/Hyperactive Subscale | Visit 1- First Intervention: Depressed Mood | Visit 2- First Intervention: Depressed Mood | Visit 3- First Intervention: Depressed Mood | Visit 4- First Intervention: Depressed Mood | Visit 5- First Intervention: Depressed Mood | Visit 6- Second Intervention: Depressed Mood | Visit 7- Second Intervention: Depressed Mood | Visit 8- Second Intervention: Depressed Mood | Visit 9- Second Intervention: Depressed Mood | Visit 10- Second Intervention: Depressed Mood | Follow-up: Depressed Mood Subscale | Visit 1- First Intervention: General Anxiety | Visit 2- First Intervention: General Anxiety | Visit 3- First Intervention: General Anxiety | Visit 4- First Intervention: General Anxiety | Visit 5- First Intervention: General Anxiety | Visit 6- Second Intervention: General Anxiety | Visit 7- Second Intervention: General Anxiety | Visit 8- Second Intervention: General Anxiety | Visit 9- Second Intervention: General Anxiety | Visit 10- Second Intervention: General Anxiety | Follow-up: General Anxiety Subscale | Visit 1- First Intervention: Obsessive Compulsive | Visit 2- First Intervention: Obsessive Compulsive | Visit 3- First Intervention: Obsessive Compulsive | Visit 4- First Intervention: Obsessive Compulsive | Visit 5- First Intervention: Obsessive Compulsive | Visit 6- Second Intervention: Obsessive Compulsive | Visit 7- Second Intervention: Obsessive Compulsive | Visit 8- Second Intervention: Obsessive Compulsive | Visit 9- Second Intervention: Obsessive Compulsive | Visit 10- First Intervention: Obsessive Compulsive | Follow-up: Obsessive Compulsive Behavior Subscale | |
| Placebo First, Then rhIGF-1 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 8.00 | 6.50 | 6.00 | 6.00 | 5.00 | 5.00 | 2.00 | 4.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 2.00 | 2.00 | 8.00 | 6.00 | 6.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 4.00 | 4.00 | 5.50 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 7.00 | 7.00 | 6.00 | 5.00 | 4.00 | 6.00 | 5.00 | 5.00 | 4.00 | 4.50 | 5.00 | 4.00 | 5.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 2.00 | 3.00 | 3.50 | 6.00 | 7.00 | 6.00 | 5.00 | 5.00 | 7.00 | 5.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.50 | 3.00 |
"The ADAMS is completed by the parent/caregiver/LAR and consists of 29 items which are scored on a 4-point rating scale that combines frequency and severity ratings. The instructions ask the rater to describe the individual's behavior over the last six months on the following scale: 0 if the behavior has not occurred, 1 if the behavior occurs occasionally or is a mild problem, 2 if the behavior occurs quite often or is moderate problem, or 3 if the behavior occurs a lot or is a severe problem.~The Social Avoidance subscale of the ADAMS will be used as a primary outcome measure for this trial. The range for this subscale is 0-21. The higher the subscale score, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 3.00 |
"Each time the patient was seen after the study intervention was initiated, the clinician compared the patient's overall clinical condition to the CGI-S score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | ||||
|---|---|---|---|---|---|
| Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
"This scale is used to judge the severity of the subject's disease prior to entry into the study. The clinician will rate the severity of behavioral symptoms at baseline on a 7-point scale from not impaired to the most impaired.~The scores that correspond to each possible grouping are as follows: 1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.50 |
"The CSBS-DP was designed to measure early communication and symbolic skills in infants and young children (that is, functional communication skills of 6 month to 2 year olds). The CSBS-DP measures skills from three composites: (a) Social (emotion, eye gaze, and communication); (b) Speech (sounds and words); and (c) Symbolic (understanding and object use) and asks about developmental milestones. The data reported are the composite scores for these three categories.~The possible scores for the three composite categories are as follows:~Social Composite = 0-48; Speech Composite = 0-40; Symbolic Composite = 0-51.~A higher score indicates more advanced abilities in that area." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Social | Visit 2: Social Composite Score | Visit 3: Social Composite Score | Visit 4: Social Composite Score | Visit 5: Social Composite Score | Visit 6 - Second Intervention: Social | Visit 7 - Second Intervention: Social | Visit 8 - Second Intervention: Social | Visit 9 - Second Intervention: Social | Visit 10 - Second Intervention: Social | Follow-up: Social Composite Score | Visit 1 - First Intervention: Speech | Visit 2 - First Intervention: Speech | Visit 3 - First Intervention: Speech | Visit 4 - First Intervention: Speech | Visit 5 - First Intervention: Speech | Visit 6 - Second Intervention: Speech | Visit 7 - Second Intervention: Speech | Visit 8 - Second Intervention: Speech | Visit 9 - Second Intervention: Speech | Visit 10 - Second Intervention: Speech | Follow-up: Speech Composite Score | Visit 1 - First Intervention: Symbolic | Visit 2 - First Intervention: Symbolic | Visit 3 - First Intervention: Symbolic | Visit 4 - First Intervention: Symbolic | Visit 5 - First Intervention: Symbolic | Visit 6 - Second Intervention: Symbolic | Visit 7 - Second Intervention: Symbolic | Visit 8 - Second Intervention: Symbolic | Visit 9 - Second Intervention: Symbolic | Visit 10 - Second Intervention: Symbolic | Follow-up: Symbolic Composite Score | |
| Placebo First, Then rhIGF-1 | 19.00 | 20.00 | 18.00 | 18.00 | 20.00 | 18.00 | 20.00 | 21.00 | 21.00 | 22.50 | 22.50 | 4.00 | 3.00 | 5.00 | 5.50 | 6.50 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 9.50 | 10.50 | 10.50 | 12.00 | 11.50 | 13.00 | 10.25 | 11.50 | 11.50 | 13.75 | 14.25 |
| rhIGF-1 First, Then Placebo | 22.00 | 24.00 | 24.00 | 24.00 | 23.00 | 28.00 | 25.00 | 27.00 | 29.00 | 27.00 | 28.00 | 7.00 | 5.00 | 8.00 | 5.00 | 8.00 | 8.50 | 7.00 | 6.50 | 5.00 | 7.25 | 6.00 | 14.00 | 14.50 | 15.00 | 14.00 | 16.50 | 18.50 | 17.00 | 17.00 | 18.00 | 17.00 | 18.00 |
"The Kerr clinical severity scale (Kerr scale) is a quantitative measure of global disease severity. The Kerr scale is a summation of individual items related to Rett syndrome phenotypic characteristics. The items are based on the severity or degree of abnormality of each characteristic on a discrete scale (0, 1, 2) with the highest level corresponding to the most severe or most abnormal presentations.~The possible range of scores is 0-48. The higher the score, the more severe the symptoms." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||
|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 16.50 | 15.00 | 15.00 | 14.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 18.00 | 19.00 | 20.00 |
"The MSEL is a standardized developmental test for children ages 3 to 68 months consisting of five subscales: gross motor, fine motor, visual reception, expressive language, and receptive language.~The raw score is reported for each subscale domain. The potential score ranges are as follows:~Visual Reception: 33 items, score range=0-50, Fine Motor: 30 items, score range= 0-49, Receptive Language: 33 items, score range= 0-48, Expressive Language: 28 items, score range= 0-50. The gross motor subscale was not included in this population.~A higher raw score indicates more advanced abilities in that section." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Visual Reception | Visit 5- First Intervention: Visual Reception | Visit 6- Second Intervention: Visual Reception | Visit 10: Visual Reception Raw Score | Visit 1- First Intervention: Fine Motor | Visit 5- First Intervention: Fine Motor | Visit 6- Second Intervention: Fine Motor | Visit 10- Second Intervention: Fine Motor | Visit 1- First Intervention: Receptive Language | Visit 5- First Intervention: Receptive Language | Visit 6- Second Intervention: Receptive Language | Visit 10- Second Intervention: Receptive Language | Visit 1- First Intervention: Expressive Language | Visit 5- First Intervention: Expressive Language | Visit 6- Second Intervention: Expressive Language | Visit 10- Second Intervention: Expressive Language | |
| Placebo First, Then rhIGF-1 | 17.00 | 26.00 | 23.00 | 28.00 | 10.00 | 9.00 | 11.00 | 9.00 | 20.00 | 30.00 | 31.00 | 31.00 | 8.00 | 9.00 | 6.00 | 8.00 |
| rhIGF-1 First, Then Placebo | 26.00 | 39.50 | 42.00 | 44.00 | 7.00 | 7.00 | 10.00 | 8.50 | 25.50 | 32.00 | 38.00 | 36.50 | 9.00 | 8.00 | 10.00 | 8.00 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.50 | 4.70 | 5.65 | 5.05 | 4.80 | 4.95 | 4.55 | 5.65 | 4.15 | 4.80 | 5.60 |
| rhIGF-1 First, Then Placebo | 8.80 | 4.80 | 5.35 | 5.10 | 5.15 | 5.20 | 4.65 | 5.00 | 5.15 | 5.05 | 5.08 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.75 | 4.50 | 5.85 | 5.00 | 5.00 | 5.35 | 5.50 | 5.15 | 3.80 | 4.90 | 5.15 |
| rhIGF-1 First, Then Placebo | 6.35 | 5.25 | 5.95 | 5.40 | 5.45 | 7.10 | 5.85 | 5.00 | 5.13 | 4.95 | 5.20 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.85 | 4.70 | 5.65 | 4.15 | 5.00 | 6.20 | 4.80 | 4.85 | 4.60 | 4.13 | 4.55 |
| rhIGF-1 First, Then Placebo | 5.70 | 5.00 | 5.20 | 5.35 | 5.10 | 5.35 | 4.95 | 5.15 | 5.25 | 4.55 | 5.10 |
"As part of each visit after the study intervention was initiated, the parent/caregiver was asked to compare the patient's overall clinical condition to the score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
"The PGI-S is the parent version of the CGI-S. Parents/caregivers/LAR are asked to rate the severity of their child's symptoms at baseline on a 7-point scale from not at all impaired to the most impaired. The parents/caregivers/LAR will complete the PGI-S at each study visit.~The scores that correspond to each possible grouping are as follows:~1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 6.00 | 6.00 | 5.00 | 4.00 |
"Respiratory data was collected using non-invasive respiratory inductance plethysmography from a BioCapture® recording device. BioCapture® is a child-friendly measurement device that can record from 1 to 12 physiological signal transducers in a time-locked manner. It can be configured with the pediatric chest and abdominal plethysmography bands and the 3 lead ECG signals we plan to use for monitoring cardiac safety throughout the study. Each transducer is placed on the patient independently to provide a customized fit that yields the highest signal quality for each patient irrespective of body shape and proportion. The transducer signals captured by the BioCapture® are transmitted wirelessly to a laptop computer where all signals are displayed in real-time.~The apnea index is given as apneas/hour. Data on apneas greater than or equal to 10 seconds are displayed below. The higher the frequency of apnea, the more severe the breathing abnormality." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | Apneas/Hour (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Apnea Index | Visit 3 - First Intervention: Apnea Index | Visit 5 - First Intervention: Apnea Index | Visit 6 - Second Intervention: Apnea Index | Visit 8 - Second Intervention: Apnea Index | Visit 10 - Second Intervention: Apnea Index | |
| Placebo First, Then rhIGF-1 | 7.58 | 4.80 | 6.93 | 7.90 | 7.28 | 8.91 |
| rhIGF-1 First, Then Placebo | 4.05 | 3.48 | 3.07 | 3.62 | 5.55 | 5.56 |
"The RSBQ is a parent-completed measure of abnormal behaviors typically observed in individuals with RTT. Each item, grouped into eight subscales, is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of each subscale is reported. The higher the score, the more severe the symptoms of that subscale in the participant.~The range for each subscale is as follows:~General Mood: 0-16 Body rocking and expressionless face: 0-14 Hand behaviors: 0-12 Breathing Problems: 0-10 Repetitive Face Movements: 0-8 Night-time behaviors: 0-6 Walking Standing: 0-4~The fear/anxiety subscale was used as a primary outcome measure in this study and results can be found in that section." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: General Mood | Visit 2- First Intervention: General Mood | Visit 3- First Intervention: General Mood | Visit 4- First Intervention: General Mood | Visit 5- First Intervention: General Mood | Visit 6- Second Intervention: General Mood | Visit 7- Second Intervention: General Mood | Visit 8- Second Intervention: General Mood | Visit 9- Second Intervention: General Mood | Visit 10- Second Intervention: General Mood | Follow-up: General Mood | Visit 1- First Intervention: Body Rocking | Visit 2- First Intervention: Body Rocking | Visit 3- First Intervention: Body Rocking | Visit 4- First Intervention: Body Rocking | Visit 5- First Intervention: Body Rocking | Visit 6- Second Intervention: Body Rocking | Visit 7- Second Intervention: Body Rocking | Visit 8- Second Intervention: Body Rocking | Visit 9- Second Intervention: Body Rocking | Visit 10- Second Intervention: Body Rocking | Followup: Body Rocking | Visit 1- First Intervention: Hand Behaviors | Visit 2- First Intervention: Hand Behaviors | Visit 3- First Intervention: Hand Behaviors | Visit 4- First Intervention: Hand Behaviors | Visit 5- First Intervention: Hand Behaviors | Visit 6- Second Intervention: Hand Behaviors | Visit 7- Second Intervention: Hand Behaviors | Visit 8- Second Intervention: Hand Behaviors | Visit 9- Second Intervention: Hand Behaviors | Visit 10- Second Intervention: Hand Behaviors | Follow-up: Hand Behaviors | Visit 1- First Intervention: Breathing Problems | Visit 2- First Intervention: Breathing Problems | Visit 3- First Intervention: Breathing Problems | Visit 4- First Intervention: Breathing Problems | Visit 5- First Intervention: Breathing Problems | Visit 6- Second Intervention: Breathing Problems | Visit 7- Second Intervention: Breathing Problems | Visit 8- Second Intervention: Breathing Problems | Visit 9- Second Intervention: Breathing Problems | Visit 10- Second Intervention: Breathing Problems | Follow-up: Breathing Problems | Visit 1- First Intervention: Repetitive Face Movem | Visit 2- First Intervention: Repetitive Face Movem | Visit 3- First Intervention: Repetitive Face Movem | Visit 4- First Intervention: Repetitive Face Movem | Visit 5- First Intervention: Repetitive Face Movem | Visit 6- Second Intervention: Repetitive Face Mov | Visit 7- Second Intervention: Repetitive Face Mov | Visit 8- Second Intervention: Repetitive Face Mov | Visit 9- Second Intervention: Repetitive Face Mov | Visit 10- Second Intervention: Repetitive Face Mov | Follow-up: Repetitive Face Movements | Visit 1- First Intervention: Night time Behaviors | Visit 2- First Intervention: Night time Behaviors | Visit 3- First Intervention: Night time Behaviors | Visit 4- First Intervention: Night time Behaviors | Visit 5- First Intervention: Night time Behaviors | Visit 6- Second Intervention: Night time Behavior | Visit 7- Second Intervention: Night time Behavior | Visit 8- Second Intervention: Night time Behavior | Visit 9- Second Intervention: Night time Behavior | Visit 10- Second Intervention: Night time Behavior | Follow-up: Night time Behaviors | Visit 1- First Intervention: Walking/Standing | Visit 2- First Intervention: Walking/Standing | Visit 3- First Intervention: Walking/Standing | Visit 4- First Intervention: Walking/Standing | Visit 5- First Intervention: Walking/Standing | Visit 6- Second Intervention: Walking/Standing | Visit 7- Second Intervention: Walking/Standing | Visit 8- Second Intervention: Walking/Standing | Visit 9- Second Intervention: Walking/Standing | Visit 10- Second Intervention: Walking/Standing | Follow-up: Walking/Standing | |
| Placebo First, Then rhIGF-1 | 7.00 | 5.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.50 | 5.00 | 6.00 | 4.00 | 5.50 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 5.00 | 5.00 | 4.00 | 5.00 | 4.50 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.50 | 6.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 4.50 | 6.00 | 5.00 | 6.00 | 5.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 1.50 | 2.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 4.00 | 2.00 | 2.00 | 1.00 | 2.50 | 2.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 4.00 | 3.00 | 4.00 | 4.00 | 8.00 | 8.00 | 8.00 | 9.00 | 9.00 | 8.00 | 9.00 | 9.00 | 7.00 | 9.00 | 8.50 | 4.00 | 4.00 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 1.50 | 2.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
"The RSBQ is an informant/parent-completed measure of abnormal behaviors typically observed in individuals with RTT, which is completed by a parent/caregiver/LAR. Each item, grouped into eight domains/factors: General mood, Breathing problems, Body rocking and expressionless face, Hand behaviors, Repetitive face movements, Night-time behaviors, Fear/anxiety and Walking/standing), is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of items in each subscale is reported.~For the fear/anxiety subscale, the sum total could be between 0-8. The higher the sum total score, the greater the frequency of fear/anxiety behaviors." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 4.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 5.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.50 |
"The VABS-II is a survey designed to assess personal and social functioning. Within each domain (Communication, Daily Living Skills, Socialization, and Motor Skills), items can given a score of 2 if the participant successfully performs the activity usually; a 1 if the participant successfully performs the activity sometimes, or needs reminders; a 0 if the participant never performs the activity, and a DK if the parent/caregiver is unsure of the participant's ability for an item.~The raw scores in each sub-domain are reported and the ranges for these are as follows: [Communication Domain], Receptive Language=0-40, Expressive Language=0-108, Written Language=0-50; [Daily Living Skills Domain], Personal=0-82, Domestic=0-48, Community=0-88; [Socialization Domain], Interpersonal Relationships=0-76, Play and Leisure Time=0-62, Coping Skills=0-60; [Motor Skills Domain]: Gross Motor Skills=0-80, Fine Motor Skills=0-72.~A higher score indicates more advanced abilities." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Receptive | Visit 5 - First Intervention: Receptive | Visit 6 - Second Intervention: Receptive Language | Visit 10 - Second Intervention: Receptive Language | Visit 1 - First Intervention: Expressive | Visit 5 - First Intervention: Expressive | Visit 6 - Second Intervention: Expressive Lang. | Visit 10 - Second Intervention: Expressive Lang. | Visit 1 - First Intervention: Written | Visit 5 - First Intervention: Written | Visit 6: - Second Intervention Written Language | Visit 10 - Second Intervention: Written Language | Visit 1 - First Intervention: Personal | Visit 5 - First Intervention: Personal | Visit 6 - Second Intervention: Personal | Visit 10 - Second Intervention: Personal | Visit 1 - First Intervention: Domestic | Visit 5 - First Intervention: Domestic | Visit 6 - Second Intervention: Domestic | Visit 10 - Second Intervention: Domestic | Visit 1 - First Intervention: Community | Visit 5 - First Intervention: Community | Visit 6 - Second Intervention: Community | Visit 10 - Second Intervention: Community | Visit 1 - First Intervention: Interpersonal Rel. | Visit 5 - First Intervention: Interpersonal Rel. | Visit 6 - Second Intervention: Interpersonal Rel. | Visit 10 - Second Intervention: Interpersonal Rel. | Visit 1 - First Intervention: Play and Leisure | Visit 5 - First Intervention: Play and Leisure | Visit 6 - Second Intervention: Play and Leisure | Visit 10 - Second Intervention: Play and Leisure | Visit 1 - First Intervention: Coping Skills | Visit 5 - First Intervention: Coping Skills | Visit 6 - Second Intervention: Coping Skills | Visit 10 - Second Intervention: Coping Skills | Visit 1 - First Intervention: Gross Motor | Visit 5 - First Intervention: Gross Motor | Visit 6 - Second Intervention: Gross Motor | Visit 10 - Second Intervention: Gross Motor | Visit 1 - First Intervention: Fine Motor | Visit 5 - First Intervention: Fine Motor | Visit 6 - Second Intervention: Fine Motor | Visit 10 - Second Intervention: Fine Motor | |
| Placebo First, Then rhIGF-1 | 13.00 | 15.00 | 18.00 | 20.00 | 16.00 | 17.00 | 18.00 | 20.00 | 0.00 | 0.00 | 4.00 | 6.00 | 9.00 | 10.00 | 9.00 | 10.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 2.00 | 18.00 | 18.00 | 19.00 | 20.00 | 8.00 | 11.00 | 12.00 | 11.00 | 3.00 | 2.00 | 3.00 | 4.00 | 31.00 | 34.00 | 27.00 | 27.00 | 6.00 | 6.00 | 7.00 | 5.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 21.00 | 22.00 | 24.50 | 18.00 | 22.00 | 25.00 | 24.00 | 4.00 | 5.00 | 7.00 | 7.00 | 8.00 | 9.00 | 8.50 | 9.50 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 3.00 | 5.00 | 5.00 | 21.00 | 22.00 | 21.00 | 22.50 | 13.00 | 12.00 | 13.00 | 12.50 | 3.00 | 4.00 | 6.00 | 4.50 | 10.00 | 10.00 | 11.50 | 10.50 | 2.00 | 3.00 | 4.00 | 4.00 |
8 reviews available for amphetamine and Body Weight
| Article | Year |
|---|---|
Effect of stimulants on height and weight: a review of the literature.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Central Nervou | 2008 |
Studies of cocaine- and amphetamine-regulated transcript (CART) knockout mice.
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Central Nervous System Stimulants; Cocaine; Mic | 2006 |
The current status of antiobesity drugs.
Topics: Adult; Amphetamine; Appetite Depressants; Body Weight; Child; Diethylpropion; Dose-Response Relation | 1984 |
Direct and indirect thermogenic effects of anorectic drugs.
Topics: Adipose Tissue, Brown; Amphetamine; Animals; Appetite Depressants; Body Temperature Regulation; Body | 1985 |
[Obesity-background and treatment].
Topics: Age Factors; Amphetamine; Appetite Regulation; Body Weight; Diet, Reducing; Fatty Acids; Female; Fen | 1972 |
The management of obesity.
Topics: Adolescent; Adult; Amphetamine; Body Weight; Child; Chlorphentermine; Diet, Reducing; Diethylpropion | 1972 |
Relationship of dopamine neural systems to the behavioral alterations produced by 6-hydroxydopamine administration into brain.
Topics: Amphetamine; Animals; Behavior, Animal; Body Temperature Regulation; Body Weight; Brain; Dihydroxyph | 1974 |
Hepatic receptors and the neurophysiological mechanisms controlling feeding behavior.
Topics: Action Potentials; Amino Acids; Amphetamine; Animals; Anorexia Nervosa; Body Temperature; Body Weigh | 1971 |
4 trials available for amphetamine and Body Weight
| Article | Year |
|---|---|
Levoamphetamine vs dextroamphetamine in minimal brain dysfunction. Replication, time response, and differential effect by diagnostic group and family rating.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Weight; Child; Clin | 1976 |
Levoamphetamine and dextroamphetamine: comparative efficacy in the hyperkinetic syndrome. Assessment by target symptoms.
Topics: Aggression; Amphetamine; Attention; Body Weight; Child; Clinical Trials as Topic; Dextroamphetamine; | 1972 |
Effectiveness of weight reduction involving "diet pills".
Topics: Adult; Amphetamine; Body Weight; Cathartics; Clinical Trials as Topic; Diet, Reducing; Digitalis Gly | 1972 |
Hyperinsulinemia secondary to chronic administration of mazindol and d-amphetamine.
Topics: Acetoacetates; Adult; Amphetamine; Appetite Depressants; Blood Glucose; Body Weight; Cholesterol; Cl | 1971 |
175 other studies available for amphetamine and Body Weight
| Article | Year |
|---|---|
Changes in the Behavior and Body Weight of Mature, Adult Male Wistar Han Rats after Reduced Social Grouping and Social Isolation.
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Exploratory Behavior; Male; Rats; Rats, Wistar; | 2022 |
Effect of a change in housing conditions on body weight, behavior and brain neurotransmitters in male C57BL/6J mice.
Topics: Amphetamine; Analysis of Variance; Animals; Body Weight; Brain; Chromatography, High Pressure Liquid | 2017 |
6 Hz corneal kindling in mice triggers neurobehavioral comorbidities accompanied by relevant changes in c-Fos immunoreactivity throughout the brain.
Topics: Amphetamine; Animals; Body Weight; Brain; Central Nervous System Stimulants; Cornea; Disease Models, | 2018 |
Differential effects of estrogen and testosterone on auditory sensory gating in rats.
Topics: Amphetamine; Animals; Apomorphine; Auditory Perception; Body Weight; Central Nervous System Stimulan | 2014 |
The effects of amphetamine, butorphanol, and their combination on cocaine self-administration.
Topics: Amphetamine; Animals; Body Weight; Butorphanol; Cocaine; Conditioning, Operant; Dopamine Uptake Inhi | 2014 |
Knockdown of ventral tegmental area mu-opioid receptors in rats prevents effects of social defeat stress: implications for amphetamine cross-sensitization, social avoidance, weight regulation and expression of brain-derived neurotrophic factor.
Topics: Amphetamine; Analgesics, Opioid; Animals; Body Weight; Brain-Derived Neurotrophic Factor; Cell Count | 2015 |
Effects of gender on locomotor sensitivity to amphetamine, body weight, and fat mass in regulator of G protein signaling 9 (RGS9) knockout mice.
Topics: Amphetamine; Animals; Body Composition; Body Weight; Calorimetry, Indirect; Carbon Dioxide; Central | 2015 |
Episodic sucrose intake during food restriction increases synaptic abundance of AMPA receptors in nucleus accumbens and augments intake of sucrose following restoration of ad libitum feeding.
Topics: Amphetamine; Analysis of Variance; Animals; Body Weight; Central Nervous System Stimulants; Eating; | 2015 |
Involvement of oxidative stress in the regulation of NPY/CART-mediated appetite control in amphetamine-treated rats.
Topics: Amphetamine; Animals; Appetite Depressants; Appetite Regulation; Body Weight; Brain; Eating; Feeding | 2015 |
Neonatal exposure to amphetamine alters social affiliation and central dopamine activity in adult male prairie voles.
Topics: Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Anxiety; Arvicolinae; Body Weight; Cen | 2015 |
Procedural learning as a measure of functional impairment in a mouse model of ischemic stroke.
Topics: Amphetamine; Animals; Body Weight; Cognition Disorders; Disease Models, Animal; Functional Lateralit | 2016 |
Deficit in emotional learning in neurotrimin knockout mice.
Topics: Amphetamine; Animals; Avoidance Learning; Body Weight; Cell Adhesion Molecules, Neuronal; Central Ne | 2017 |
Participation of ghrelin signalling in the reciprocal regulation of hypothalamic NPY/POMC-mediated appetite control in amphetamine-treated rats.
Topics: Acyltransferases; Amphetamine; Animals; Appetite Regulation; Body Weight; Central Nervous System Sti | 2017 |
Feeding conditions differentially affect the neurochemical and behavioral effects of dopaminergic drugs in male rats.
Topics: Amphetamine; Animals; Behavior, Animal; Blood Glucose; Body Weight; Brain Chemistry; Caloric Restric | 2008 |
Simultaneous anhedonia and exaggerated locomotor activation in an animal model of depression.
Topics: Amphetamine; Analgesics, Non-Narcotic; Analysis of Variance; Animals; Body Weight; Central Nervous S | 2009 |
The mechanism of amphetamine-induced loss of weight; a consideration of the theory of hunger and appetite.
Topics: Amphetamine; Amphetamines; Appetite; Body Weight; Humans; Hunger | 1947 |
Age-related differences in amphetamine sensitization: effects of prior drug or stress history on stimulant sensitization in juvenile and adult rats.
Topics: Age Factors; Amphetamine; Animals; Body Weight; Central Nervous System Stimulants; Female; Locomotio | 2010 |
Withdrawal from chronic exposure to amphetamine, but not nicotine, leads to an immediate and enduring deficit in motivated behavior without affecting social interaction in rats.
Topics: Amphetamine; Animals; Body Weight; Central Nervous System Stimulants; Conditioning, Operant; Depress | 2010 |
Long-term physiological and behavioral effects of exposure to a highly palatable diet during the perinatal and post-weaning periods.
Topics: Adiposity; Age Factors; Amphetamine; Animal Nutritional Physiological Phenomena; Animals; Appetite R | 2010 |
Comparison of (+)-methamphetamine, ±-methylenedioxymethamphetamine, (+)-amphetamine and ±-fenfluramine in rats on egocentric learning in the Cincinnati water maze.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Body Temperature; Body Weight; Central | 2011 |
Differential effect of amphetamine on c-fos expression in female aromatase knockout (ArKO) mice compared to wildtype controls.
Topics: Amphetamine; Animals; Aromatase; Body Weight; Female; Gene Expression; Genes, fos; Mice; Mice, Inbre | 2011 |
Individual differences in maternal response to immune challenge predict offspring behavior: contribution of environmental factors.
Topics: Age Factors; Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Antiviral Agents; Behavio | 2011 |
Amphetamine-induced incentive sensitization of sign-tracking behavior in adolescent and adult female rats.
Topics: Age Factors; Amphetamine; Analysis of Variance; Animals; Attention; Body Weight; Central Nervous Sys | 2011 |
Does prenatal methamphetamine exposure affect the drug-seeking behavior of adult male rats?
Topics: Amphetamine; Analysis of Variance; Animals; Body Weight; Cocaine; Conditioning, Operant; Disease Mod | 2011 |
Rescue of dopamine transporter function in hypoinsulinemic rats by a D2 receptor-ERK-dependent mechanism.
Topics: Amphetamine; Analysis of Variance; Animals; Blood Glucose; Body Weight; Brain; Brain Mapping; Corpus | 2012 |
Effects of perinatal exposure to palatable diets on body weight and sensitivity to drugs of abuse in rats.
Topics: Alcohol Drinking; Amphetamine; Animals; Body Weight; Dietary Fats; Eating; Female; Food Preferences; | 2012 |
The effects of isolated and enriched housing conditions on baseline and drug-induced behavioural responses in the male rat.
Topics: Amphetamine; Analysis of Variance; Animals; Anti-Anxiety Agents; Behavior, Animal; Body Weight; Cent | 2012 |
Spontaneous polydipsia in animals treated subchronically with MK-801.
Topics: Age Factors; Amphetamine; Animals; Animals, Newborn; Body Weight; Central Nervous System Stimulants; | 2013 |
Differential activation of orexin neurons by antipsychotic drugs associated with weight gain.
Topics: Amphetamine; Animals; Antipsychotic Agents; Body Weight; Carrier Proteins; Cell Count; Central Nervo | 2002 |
Attentional effects of nicotine and amphetamine in rats at different levels of motivation.
Topics: Amphetamine; Animals; Body Weight; Central Nervous System Stimulants; Food Deprivation; Ganglionic S | 2003 |
MECHANISM of weight loss by amphetamine.
Topics: Amphetamine; Amphetamines; Body Weight; Humans; Weight Loss | 1956 |
Effect of dosage level of amphetamine tartronate on weights of castrate rats.
Topics: Amphetamine; Amphetamines; Animals; Body Weight; Castration; Rats; Tartronates | 1957 |
The control of weight in hypertensives on rauwolfia and its derivatives.
Topics: Amphetamine; Amphetamines; Body Weight; Hypertension; Obesity; Rauwolfia | 1960 |
STUDIES IN EXPERIMENTAL OBESITY. IV. EFFECT OF THYROID, AMPHETAMINE AND HIGH-PROTEIN DIET ON THE REGRESSION OF EXPERIMENTAL OBESITY IN ALBINO RATS.
Topics: Amphetamine; Amphetamines; Body Weight; Diet; Dietary Proteins; Nitrogen; Obesity; Pharmacology; Pro | 1963 |
POTASSIUM 40 MEASUREMENTS OF BODY COMPOSITION.
Topics: Amphetamine; Biomedical Research; Body Composition; Body Weight; Body Weights and Measures; Drug The | 1964 |
[Loss of weight with dexedrine in medical practice].
Topics: Amphetamine; Amphetamines; Body Weight; Dextroamphetamine; Obesity | 1960 |
[The psycho-stimulating and body weight action of amphetamine in long-term administration in guinea pigs].
Topics: Amphetamine; Amphetamines; Body Weight; Body Weights and Measures; Brain; Guinea Pigs; Humans | 1962 |
Reduction in body weight and blood pressure following administration of benzphetamine hydrochloride (Didrex).
Topics: Amphetamine; Amphetamines; Benzphetamine; Blood Pressure; Body Weight; Humans; Hypertension; Obesity | 1961 |
Further evidence for the mediation of both subtypes of dopamine D1/D2 receptors and cerebral neuropeptide Y (NPY) in amphetamine-induced appetite suppression.
Topics: Amphetamine; Animals; Appetite; Behavior, Animal; Body Weight; Dopamine Agents; Dopamine Antagonists | 2003 |
Alteration in behavioral sensitivity to amphetamine after treatment with oxotremorine. Effect of dose and test environment.
Topics: Amphetamine; Analysis of Variance; Animals; Body Weight; Dopamine Agents; Dose-Response Relationship | 2003 |
Amelioration of behavioral deficits in a rat model of Huntington's disease by an excitotoxic lesion to the globus pallidus.
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Central Nervous System Stimulants; Cognition; D | 2004 |
Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Body Weight; Brain; Capsules; Cell Count; | 2004 |
Transient disruption of attentional performance following escalating amphetamine administration in rats.
Topics: Amphetamine; Animals; Attention; Body Weight; Central Nervous System Stimulants; Dose-Response Relat | 2004 |
Decreased brain docosahexaenoic acid during development alters dopamine-related behaviors in adult rats that are differentially affected by dietary remediation.
Topics: Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal; Body Weight; Brain; | 2004 |
Enhancement of amphetamine-induced locomotor response in rats on different regimens of diet restriction and 2-deoxy-D-glucose treatment.
Topics: Amphetamine; Animals; Body Weight; Caloric Restriction; Deoxyglucose; Dose-Response Relationship, Dr | 2005 |
Amphetamine-induced aggression is enhanced in rats pre-treated with the anabolic androgenic steroid nandrolone decanoate.
Topics: Aggression; Amphetamine; Amphetamines; Animals; Behavior, Animal; Body Weight; Male; Nandrolone; Nan | 2005 |
Long-term effects of extended-release mixed amphetamine salts treatment of attention- deficit/hyperactivity disorder on growth.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Body Weigh | 2005 |
Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine.
Topics: Amphetamine; Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Clozapine; Dibenzothiazepi | 2005 |
Deficits in dopamine clearance and locomotion in hypoinsulinemic rats unmask novel modulation of dopamine transporters by amphetamine.
Topics: Amphetamine; Animals; Body Weight; Diabetes Mellitus, Experimental; Dopamine; Dopamine Agents; Dopam | 2005 |
Neurorescue effects of VEGF on a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Body Weight; Brain; | 2005 |
Early maternal deprivation retards neurodevelopment in Wistar rats.
Topics: Amphetamine; Animals; Animals, Newborn; Body Weight; Dizocilpine Maleate; Eye Abnormalities; Female; | 2005 |
A threshold neurotoxic amphetamine exposure inhibits parietal cortex expression of synaptic plasticity-related genes.
Topics: Amphetamine; Animals; Body Temperature; Body Weight; Central Nervous System Stimulants; DNA, Complem | 2007 |
Early maternal deprivation reduces prepulse inhibition and impairs spatial learning ability in adulthood: no further effect of post-pubertal chronic corticosterone treatment.
Topics: Acoustic Stimulation; Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal | 2007 |
Insulin replacement restores the behavioral effects of quinpirole and raclopride in streptozotocin-treated rats.
Topics: Amphetamine; Animals; Behavior, Animal; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; | 2007 |
Chronic amphetamine treatment reduces NGF and BDNF in the rat brain.
Topics: Amphetamine; Analysis of Variance; Animals; Body Weight; Brain; Brain-Derived Neurotrophic Factor; C | 2007 |
Roles of central catecholamine and hypothalamic neuropeptide Y genome in the development of tolerance to phenylpropanolamine-mediated appetite suppression.
Topics: Amphetamine; Animals; Appetite Depressants; Body Weight; Bupropion; Catecholamines; Catheterization; | 2007 |
Behavioral and pharmacological validation of the gerbil forced-swim test: effects of neurokinin-1 receptor antagonists.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Animals; Antidepressive Agents; Antidepressive Agents, Se | 2008 |
Behavioral effects of amphetamine in streptozotocin-treated rats.
Topics: Amphetamine; Animals; Behavior, Animal; Blood Glucose; Body Weight; Conditioning, Psychological; Dia | 2008 |
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.
Topics: Adrenal Cortex Hormones; Amphetamine; Animals; Anxiety; Blotting, Western; Body Weight; Central Nerv | 2008 |
Postnatal manganese exposure alters dopamine transporter function in adult rats: Potential impact on nonassociative and associative processes.
Topics: Amphetamine; Animals; Animals, Newborn; Association Learning; Body Weight; Central Nervous System St | 2008 |
[Pharmacodynamic study of amphetamine para-chlorophenoxyacetate].
Topics: Amphetamine; Animals; Blood Pressure; Body Weight; Central Nervous System; Dextroamphetamine; Dogs; | 1966 |
Interaction of D-amphetamine and food deprivation on fixed ratio behavior of pigeons.
Topics: Amphetamine; Animals; Behavior, Animal; Birds; Body Weight; Hunger | 1967 |
Behavioural analysis of feeding: implications for the pharmacological manipulation of food intake in animals and man.
Topics: Amphetamine; Animals; Antipsychotic Agents; Appetite Depressants; Body Weight; Eating; Feeding Behav | 1980 |
Thermogenic properties of ciclazindol and mazindol in rodents.
Topics: Amphetamine; Animals; Behavior, Animal; Body Temperature Regulation; Body Weight; Energy Metabolism; | 1984 |
The effects of amphetamine or caffeine on the response to glucoprivation in rats with rostral zona incerta lesions.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Body Weight; Caffeine; Deoxyglucose; Diencephal | 1980 |
Analysis of behavioural deficits produced by lesions in the dorsal and ventral midbrain tegmentum.
Topics: Amphetamine; Animals; Body Weight; Circadian Rhythm; Deoxyglucose; Diet; Dietary Fats; Drinking Beha | 1980 |
Chemical and pharmacological studies of anorectic drugs with phenylpiperazinyl structure.
Topics: Amphetamine; Animals; Appetite Depressants; Body Weight; Chemical Phenomena; Chemistry; Drinking; Ea | 1982 |
Tolerance to anorectic drugs: pharmacological or artifactual.
Topics: Amphetamine; Animals; Appetite Depressants; Body Weight; Drug Tolerance; Eating; Female; Fenfluramin | 1981 |
Ontogeny of fenfluramine and amphetamine anorexia compared in rat pups.
Topics: Aging; Amphetamine; Animals; Body Weight; Dose-Response Relationship, Drug; Eating; Fenfluramine; Mu | 1981 |
Nicotine and amphetamine: differential tolerance and no cross-tolerance for ingestive effects.
Topics: Amphetamine; Animals; Anorexia; Body Weight; Drug Tolerance; Eating; Male; Nicotine; Rats | 1980 |
Anorexigenic effects of two amines obtained from Catha edulis Forsk. (Khat) in rats.
Topics: Alkaloids; Amphetamine; Animals; Appetite Depressants; Body Weight; Drug Tolerance; Eating; Phenylpr | 1980 |
Attenuation of amphetamine anorexia in rats following subchronic treatment with a tricyclic antidepressant.
Topics: Amphetamine; Animals; Antidepressive Agents, Tricyclic; Body Weight; Desipramine; Eating; Male; Rats | 1980 |
Excitotoxic lesions of the pedunculopontine tegmental nucleus disinhibit orofacial behaviours stimulated by microinjections of d-amphetamine into rat ventrolateral caudate-putamen.
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Caudate Nucleus; Male; Motor Activity; Mouth; N | 1995 |
Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat.
Topics: Amphetamine; Animals; Apomorphine; Body Weight; Immunohistochemistry; Levodopa; Male; Motor Activity | 1994 |
CNS monoamine levels and motoric behaviors in the hotfoot ataxic mutant.
Topics: Aging; Amphetamine; Animals; Ataxia; Biogenic Monoamines; Body Temperature; Body Weight; Central Ner | 1994 |
Brain-derived neurotrophic factor and neurotrophin-3 activate striatal dopamine and serotonin metabolism and related behaviors: interactions with amphetamine.
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Brain-Derived Neurotrophic Factor; Circadian Rh | 1994 |
Brain-derived neurotrophic factor enhances function rather than survival of intrastriatal dopamine cell-rich grafts.
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Brain Tissue Transplantation; Brain-Derived Neu | 1993 |
Body weight gain and hippocampal volumes of rats exposed neonatally to psychostimulants.
Topics: Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Body Weight; Cocaine; Hippocampus; Mal | 1993 |
BDNF enhances the functional reinnervation of the striatum by grafted fetal dopamine neurons.
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Brain Tissue Transplantation; Brain-Derived Neu | 1996 |
Decreased incidence of spontaneous mammary gland neoplasms in female F344 rats treated with amphetamine, methylphenidate, or codeine.
Topics: Amphetamine; Analgesics, Opioid; Animals; Anticarcinogenic Agents; Body Weight; Carcinogenicity Test | 1996 |
Neurobehavioral development of CD-1 mice after combined gestational and postnatal exposure to ozone.
Topics: Amphetamine; Animals; Animals, Newborn; Avoidance Learning; Behavior, Animal; Body Weight; Condition | 1995 |
Tolerance does not develop to the suppressant effects of (-)-norpseudoephedrine on ingestive behavior in the rat.
Topics: Amphetamine; Animals; Appetite Depressants; Body Weight; Diuresis; Drinking Behavior; Drug Tolerance | 1996 |
Retarded acquisition and reduced expression of conditioned locomotor activity in adult rats following repeated early maternal separation: effects of prefeeding, d-amphetamine, dopamine antagonists and clonidine.
Topics: Adrenergic alpha-Agonists; Amphetamine; Analysis of Variance; Animals; Anxiety, Separation; Behavior | 1996 |
Is the cuneiform nucleus a critical component of the mesencephalic locomotor region? An examination of the effects of excitotoxic lesions of the cuneiform nucleus on spontaneous and nucleus accumbens induced locomotion.
Topics: Amphetamine; Animals; Basal Ganglia; Body Weight; Central Nervous System Stimulants; Drinking; Eatin | 1996 |
Effects of prenatal exposure to amphetamine in the medial prefrontal cortex of the rat.
Topics: Amphetamine; Animals; Body Weight; Brain Chemistry; Central Nervous System Stimulants; Dopamine; Fem | 1996 |
Differential effects of prenatal exposure to cocaine and amphetamine on growth parameters and morphometry of the prefrontal cortex in the rat.
Topics: Amphetamine; Animals; Body Weight; Cocaine; Female; Litter Size; Male; Neurons; Organ Size; Prefront | 1996 |
Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
Topics: Adenoviridae; Amphetamine; Animals; Behavior, Animal; Body Weight; Cell Survival; Corpus Striatum; D | 1998 |
Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
Topics: Amphetamine; Animals; Antibodies; Apomorphine; Atrophy; Body Weight; Cerebral Ventricles; Corpus Str | 1999 |
Neurobehavioral effects of perinatal AZT exposure in Sprague-Dawley weaning rats.
Topics: Aging; Amphetamine; Animals; Animals, Newborn; Animals, Suckling; Anti-HIV Agents; Behavior, Animal; | 1999 |
Chronic amphetamine exposure during the preweanling period does not affect avoidance learning or novelty-seeking of adult rats.
Topics: Adrenergic Agents; Amphetamine; Animals; Avoidance Learning; Behavior, Animal; Body Weight; Drug Adm | 2001 |
Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats.
Topics: Aminopyridines; Amphetamine; Amphetamine-Related Disorders; Animals; Body Weight; Brain; Depression; | 2001 |
Testosterone (T)-induced changes in arcuate nucleus cocaine-amphetamine-regulated transcript and NPY mRNA are attenuated in old compared to young male brown Norway rats: contribution of T to age-related changes in cocaine-amphetamine-regulated transcript
Topics: Aging; Amphetamine; Animals; Arcuate Nucleus of Hypothalamus; Body Composition; Body Weight; Cocaine | 2002 |
Does extended medication with amphetamine or methylphenidate reduce growth in hyperactive children?
Topics: Adolescent; Amphetamine; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Ce | 2002 |
Role of hypothalamic neuropeptide Y (NPY) in the change of feeding behavior induced by repeated treatment of amphetamine.
Topics: Amphetamine; Animals; Body Weight; Feeding Behavior; Hypothalamus; Male; Neuropeptide Y; Oligonucleo | 2001 |
Three anorectic drugs: similar structures but different effects on brain and behavior.
Topics: Amphetamine; Animals; Appetite Depressants; Behavior; Blood Glucose; Body Weight; Brain; Dose-Respon | 1978 |
The effect of selected drugs on first-stage radioemesis in beagle dogs.
Topics: Amifostine; Amphetamine; Animals; Antiemetics; Body Weight; Chlorpromazine; Dimenhydrinate; Diphenhy | 1979 |
The effect of 5-hydroxytryptophan on food intake and on the anorexic action of amphetamine and fenfluramine.
Topics: 5-Hydroxytryptophan; Amphetamine; Analysis of Variance; Animals; Appetite; Body Weight; Brain; Fenfl | 1975 |
Metabolic level and limiting hypoxia in rodents.
Topics: Amphetamine; Animals; Body Temperature; Body Weight; Chinchilla; Diazepam; Dinitrophenols; Dose-Resp | 1975 |
Variability in development of tolerance to repeated injections of low doses of dl-amphetamine in rats.
Topics: Amphetamine; Animals; Behavior, Animal; Body Temperature; Body Weight; Circadian Rhythm; Dextroamphe | 1977 |
Lateralized hunger: ipsilateral attenuation of cortical spreading depression-induced feeding after unilateral 6-OHDA injection into the substantia nigra.
Topics: Amphetamine; Animals; Body Weight; Caudate Nucleus; Cortical Spreading Depression; Dominance, Cerebr | 1979 |
Major pharmacological effects of 6-methoxytetrahydro-beta-carboline, a drug elevating the tissue 5-hydroxytryptamine level.
Topics: Acute Disease; Amphetamine; Animals; Blood Pressure; Body Temperature; Body Weight; Carbolines; Cats | 1978 |
Lead-induced behavioral disorders in the rat: effects of amphetamine.
Topics: Amphetamine; Animals; Animals, Newborn; Behavior, Animal; Body Weight; Drug Evaluation, Preclinical; | 1978 |
Immunosuppression of rosette-forming cells.
Topics: Amphetamine; Animals; Body Weight; Caffeine; Erythrocytes; Humans; Immunity; Immunologic Techniques; | 1976 |
Inhibitions of feeding examined in rhesus monkeys with hypothalamic disconnexions.
Topics: Amphetamine; Animals; Body Weight; Brain Mapping; Environment; Feeding Behavior; Haplorhini; Hypotha | 1975 |
Serotonin reduction early in life and its effects on behavior.
Topics: 5,6-Dihydroxytryptamine; Amphetamine; Animals; Animals, Newborn; Behavior, Animal; Body Weight; Brai | 1977 |
Pontine tegmental lesions, monoamine neurons and varieties of learning.
Topics: Amphetamine; Animals; Avoidance Learning; Body Weight; Cerebellum; Cerebral Cortex; Exploratory Beha | 1977 |
Tolerance pattern of the anorexigenic action of amphetamines, fenfluramine, phenmetrazine and diethylpropion in rats.
Topics: Amphetamine; Animals; Appetite Depressants; Body Weight; Diethylpropion; Drinking; Drug Tolerance; E | 1976 |
Effect of cortisone, aldosterone and nialamide on "amphetamine stereotypies" and brain methamphetamine levels of adrenalectomized rats.
Topics: Adrenal Glands; Adrenalectomy; Aldosterone; Amphetamine; Animals; Behavior; Body Weight; Brain; Cort | 1976 |
[Mode of action and indication for appetite depressants in the treatment of obesity].
Topics: Amphetamine; Amphetamines; Appetite Depressants; Behavior Therapy; Body Weight; Chemical Phenomena; | 1975 |
Potentiation of amphetamine-induced arousal by food deprivation: effect of hypothalamic lesions.
Topics: Amphetamine; Animals; Arousal; Body Weight; Feeding Behavior; Food Deprivation; Hypothalamus; Hypoth | 1975 |
The duration of tolerance to the anorexigenic effect of amphetamine in rats.
Topics: Amphetamine; Animals; Appetite; Body Weight; Drug Tolerance; Eating; Male; Rats; Time Factors | 1975 |
Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum.
Topics: Amphetamine; Animals; Apomorphine; Body Weight; Corpus Striatum; Dopamine; Humans; Hydroxydopamines; | 1975 |
Effects of lateral hypothalamic lesions on consummatory behavior in developing rats.
Topics: Age Factors; Amphetamine; Animals; Animals, Newborn; Body Weight; Dose-Response Relationship, Drug; | 1975 |
Conditioned avoidance behavior in pretrained rats intermittently treated with addictive drugs.
Topics: Amphetamine; Animals; Avoidance Learning; Body Weight; Conditioning, Operant; Dose-Response Relation | 1975 |
Hyperactivity and altered amphetamine sensitivity in premature juvenile rats.
Topics: Amphetamine; Animals; Animals, Newborn; Body Weight; Cesarean Section; Female; Gestational Age; Moto | 1992 |
Relationship between amphetamine and environmentally induced stereotypies in pigs.
Topics: Adipose Tissue; Amphetamine; Animals; Body Weight; Drinking Behavior; Environment; Female; Food Depr | 1992 |
Effects of early environmental experience on self-administration of amphetamine and barbital.
Topics: Amphetamine; Animals; Barbital; Behavior, Animal; Body Weight; Environment; Female; Male; Rats; Self | 1992 |
Temperature-dependent effects of maternal separation on growth, activity, and amphetamine sensitivity in the rat.
Topics: Amphetamine; Animals; Arousal; Behavior, Animal; Body Weight; Brain; Female; Locomotion; Male; Mater | 1992 |
Endocrine, immune, and neurochemical changes in rats during withdrawal from chronic amphetamine intoxication.
Topics: Adrenocorticotropic Hormone; Amphetamine; Animals; Biomarkers; Body Weight; Brain Chemistry; Cortico | 1991 |
Estradiol enhances behavioral sensitization to cocaine and amphetamine-stimulated striatal [3H]dopamine release.
Topics: Amphetamine; Animals; Body Weight; Cocaine; Corpus Striatum; Dopamine; Drug Synergism; Estradiol; Fe | 1991 |
Time-, schedule-, and reinforcer-dependent effects of pimozide and amphetamine.
Topics: Amphetamine; Animals; Body Weight; Brain Chemistry; Conditioning, Operant; Food Deprivation; Male; P | 1991 |
Physical and behavioral development in rats after late prenatal exposure to diazepam.
Topics: Amphetamine; Animals; Anticonvulsants; Avoidance Learning; Behavior, Animal; Body Temperature; Body | 1990 |
Decreases in spontaneous tumors in rats and mice after treatment with amphetamine.
Topics: Adrenal Gland Neoplasms; Amphetamine; Animals; Body Weight; Eating; Eye Neoplasms; Female; Harderian | 1991 |
Effect of enantiomers of deprenyl (selegiline) and amphetamine on physical abuse liability and cortical electrical activity in rats.
Topics: Amphetamine; Animals; Body Weight; Cerebral Cortex; Codeine; Electric Conductivity; Electroencephalo | 1990 |
Dietary modulation of the anorectic potency of amphetamine.
Topics: Amphetamine; Animals; Appetite Depressants; Body Weight; Diet; Dietary Carbohydrates; Dietary Fats; | 1990 |
Neurochemical effects of prenatal haloperidol exposure.
Topics: Amphetamine; Animals; Body Weight; Brain Chemistry; Female; Haloperidol; Male; Pregnancy; Pregnancy | 1989 |
Repeated amphetamine: reduced dopamine neuronal responsiveness to apomorphine but not quinpirole.
Topics: Amphetamine; Animals; Apomorphine; Body Weight; Dopamine; Dopamine Agents; Electrophysiology; Ergoli | 1989 |
Behavior, striatal and nucleus accumbens field potential patterns and dopamine levels in rats given amphetamine continuously.
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Corpus Striatum; Dopamine; Electrodes, Implante | 1989 |
Alterations in behavioral and striatal dopamine asymmetries induced by prenatal stress.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Behavior, Animal; Body Weight; Caudate Nucleus | 1989 |
Discriminative stimulus properties of amphetamine and other stimulants in lead-exposed and normal rats.
Topics: Amphetamine; Animals; Apomorphine; Body Weight; Caffeine; Central Nervous System Stimulants; Discrim | 1986 |
An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice.
Topics: Amphetamine; Animals; Appetite Depressants; Body Weight; Calcitonin; Dextroamphetamine; Drug Toleran | 1987 |
Interaction between chronic amphetamine and neuroleptic treatments on oral behavior in rats.
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Drug Interactions; Dyskinesia, Drug-Induced; Fe | 1987 |
Magnesium deficiency alters aggressive behavior and catecholamine function.
Topics: Aggression; Agonistic Behavior; Amphetamine; Animals; Apomorphine; Body Weight; Catecholamines; Fema | 1988 |
The effect of previous d-amphetamine treatment on the disposition and lethality of fenfluramine in the rat.
Topics: Amphetamine; Animals; Body Weight; Drug Interactions; Fenfluramine; Half-Life; Injections, Intraperi | 1985 |
Ten years of experience with 1,000 hyperactive children in a private practice.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Body Height; Body Weig | 1985 |
A study of the factors affecting the sleeping time following intracerebroventricular administration of pentobarbitone sodium: effect of prior administration of centrally active drugs.
Topics: Aging; Amphetamine; Animals; Anti-Anxiety Agents; Barbiturates; Body Weight; Carbon Radioisotopes; C | 1974 |
The influence of cinanserin and selected pharmacologic agents on experimental allergic encephalomyelitis (EAE).
Topics: 5-Hydroxytryptophan; Amphetamine; Anilides; Animals; Azathioprine; Body Weight; Chlorpheniramine; Ci | 1971 |
Biochemical changes in rat liver in response to treatment with drugs and other agents. 3. Effects of centrally acting drugs.
Topics: Aminopyrine; Amphetamine; Animals; Antidepressive Agents; Body Weight; Chlorpromazine; Cytochromes; | 1969 |
The antidiuretic activity of the hypothalamus, hypophysis and blood plasma under various states of water metabolism and adrenergic transmission.
Topics: Amphetamine; Animals; Body Weight; Dehydration; Guinea Pigs; Hematocrit; Hypothalamo-Hypophyseal Sys | 1968 |
The effect of sodium barbitone, alone and together with ACTH and amphetamine, on the behaviour of the rat in the multiple "T" maze.
Topics: Adrenocorticotropic Hormone; Amphetamine; Animals; Barbiturates; Behavior, Animal; Body Weight; Cent | 1969 |
Amphetamine abuse: a "speed" trap.
Topics: Adult; Affect; Amphetamine; Arousal; Body Weight; Diagnosis, Differential; Female; Hospitalization; | 1971 |
Food intake and amphetamine anorexia after selective forebrain norepinephrine loss.
Topics: Amphetamine; Animals; Appetite; Body Weight; Brain Chemistry; Cerebral Cortex; Desipramine; Drinking | 1974 |
Simulation of the apparent effects of mebanazine on growth hormone by pair-feeding of control animals.
Topics: Amphetamine; Animals; Blood Glucose; Body Weight; Drug Synergism; Epiphyses; Feeding Behavior; Growt | 1969 |
The pharmacology of iprindole, a new antidepressant.
Topics: Acetylcholine; Amitriptyline; Amphetamine; Animals; Antidepressive Agents; Appetite; Atropine; Bleph | 1969 |
Bromoperidol, a new potent neuroleptic of the butyrophenone series. Comparative pharmacology of bromoperidol and haloperidol.
Topics: Administration, Oral; Amphetamine; Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Bleph | 1974 |
Dose-dependent differences of amphetamine levels in brain and heart of adult and developing mice.
Topics: Age Factors; Amphetamine; Animals; Body Weight; Brain; Culture Techniques; Dose-Response Relationshi | 1974 |
The effects of p-chloroamphetamine on instrumental conditioning in the rat.
Topics: Amphetamine; Amphetamines; Animals; Body Weight; Brain Chemistry; Chlorine; Conditioning, Operant; D | 1974 |
Narcolepsy and cataplexy. Clinical features, treatment and cerebrospinal fluid findings.
Topics: Adult; Amphetamine; Aspartic Acid; Body Weight; Cataplexy; Cerebrospinal Fluid Proteins; Dextroamphe | 1974 |
Central action of anorexic agents: effects of amphetamine and fenfluramine in rats with lateral hypothalamic lesions.
Topics: Amphetamine; Analysis of Variance; Animals; Appetite Depressants; Body Weight; Feeding Behavior; Fen | 1974 |
Anorectic activity of some amphetamine-derivatives with low CNS stimulating potency.
Topics: Administration, Oral; Amphetamine; Animals; Appetite Depressants; Body Temperature; Body Weight; Cen | 1972 |
Effects of the administration of catecholamine-depleting drugs on the thyroid function of the rat.
Topics: Aminocaproates; Amphetamine; Animals; Body Weight; Catecholamines; Cold Temperature; Guanethidine; H | 1972 |
Selective potentiation of locomotor effects of amphetamine by midbrain raphé lesions.
Topics: Amphetamine; Animals; Arousal; Behavior, Animal; Body Weight; Dose-Response Relationship, Drug; Eati | 1972 |
The action of adrenergic anorexigenic substances on rats recovered from lateral hypothalamic lesions.
Topics: Amphetamine; Animals; Appetite Regulation; Body Weight; Circadian Rhythm; Eating; Epinephrine; Feedi | 1973 |
Dissociation of the anorexic effects of fenfluramine and amphetamine following intrahypothalamic injection.
Topics: Amphetamine; Animals; Appetite Depressants; Body Weight; Feeding Behavior; Fenfluramine; Hypothalamu | 1973 |
The effects of chronic fenfluramine administration on behaviour and body weight.
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Drug Tolerance; Fenfluramine; Grooming; Humans; | 1973 |
Treatment of compulsive eating disturbances with anticonvulsant medication.
Topics: Adolescent; Adult; Amphetamine; Anorexia Nervosa; Body Image; Body Weight; Compulsive Behavior; Depr | 1974 |
Long-term effects of 4-chloroamphetamine on brain 5-hydroxyindole metabolism in rats.
Topics: Amphetamine; Animals; Body Weight; Brain; Brain Chemistry; Chlorine; Depression, Chemical; Hydroxyin | 1974 |
[Comparative action of fenfluramine and amphetamine in rats with hypothalamic obesity].
Topics: Amphetamine; Animal Nutritional Physiological Phenomena; Animals; Appetite Depressants; Body Weight; | 1969 |
Drug-induced alterations in the activity of rat brain cholinergic enzymes. I. In vitro and in vivo effect of amphetamine.
Topics: Acetylcholinesterase; Acyltransferases; Amphetamine; Animals; Behavior, Animal; Body Weight; Brain; | 1972 |
Effects of amphetamine and pilocarpine on eating behavior in rats with chronically low acetylcholinesterase levels.
Topics: Acetylcholinesterase; Amphetamine; Animal Nutritional Physiological Phenomena; Animals; Body Weight; | 1972 |
Excretion of amphetamines in human sweat.
Topics: Amphetamine; Body Weight; Chromatography, Gas; Humans; Hydrogen-Ion Concentration; Mass Spectrometry | 1972 |
The influence of prolonged amphetamine treatment and amphetamine withdrawal on brain biogenic amine content and behaviour in the rat.
Topics: Amphetamine; Animals; Body Weight; Brain Chemistry; Central Nervous System; Cerebellum; Drug Toleran | 1971 |
[Influence of cyproheptadine on food intake in animal experiments].
Topics: Amphetamine; Animals; Appetitive Behavior; Behavior, Animal; Body Weight; Cricetinae; Cyproheptadine | 1971 |
Ontogeny of amphetamine anorexia and insulin hyperphagia in the rat.
Topics: Age Factors; Amphetamine; Animals; Animals, Newborn; Anorexia Nervosa; Appetite Regulation; Body Wei | 1971 |
Interaction of the effects of reserpine and amphetamine on food and water intake.
Topics: Amphetamine; Animals; Body Weight; Drinking Behavior; Drug Antagonism; Feeding and Eating Disorders; | 1971 |
Pharmacology of phentermine.
Topics: Amphetamine; Animals; Appetite; Appetite Depressants; Blood Pressure; Body Weight; Cardiovascular Sy | 1969 |
A determination of the anorexigenic potential of dl-amphetamine, d-amphetamine, l-amphetamine and phentermine.
Topics: Amphetamine; Animals; Appetite; Appetite Depressants; Body Weight; Dextroamphetamine; Drug Tolerance | 1969 |
Development of hormonal control over food intake and body weight in female rats.
Topics: Amphetamine; Animals; Appetitive Behavior; Body Weight; Estradiol; Estrogens; Feeding Behavior; Fema | 1970 |
Obesity, the nutritional spook.
Topics: Amphetamine; Body Weight; Child; Diet, Reducing; Dietary Fats; Edible Grain; Female; Humans; Insuran | 1971 |
A mechanism for the development of tolerance to amphetamine in rats.
Topics: Amphetamine; Animals; Behavior, Animal; Body Temperature; Body Weight; Brain Chemistry; Drug Toleran | 1971 |
Actions of sympathomimetic amines on the isolated light organ of the firefly Photinus pyralis.
Topics: Amphetamine; Animals; Body Weight; Insecta; Isoproterenol; Luminescent Measurements; Male; Norepinep | 1968 |
[Experimental studies with the new appetite depressant N-(3-chlorpropyl)-1-methyl-2-phenylethylamine hydrochloride (Ro 4-5282)].
Topics: Amphetamine; Animals; Appetite; Appetite Depressants; Blood Pressure; Body Weight; Carbohydrate Meta | 1969 |
Hypothalamic lesions and disinhibition of feeding.
Topics: Amphetamine; Animals; Body Weight; Hunger; Hypothalamus; Self Stimulation | 1965 |
Effect of amphetamine on pregnancy in ICR-JCL mice.
Topics: Amphetamine; Animals; Body Weight; Female; Fetus; Mice; Pregnancy; Pregnancy, Animal | 1965 |
[Feeding behavior of rats. Frequency and size of the meals under the influence of amphetamine].
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Eating; Homeostasis; Hypothalamus; Male; Nutrit | 1966 |